Roche comes up with a new system to offer a fully-automated molecular system to labs

0 162

Roche, on Thursday, announced the launch of a new molecular laboratory instrument named ‘Cobas® 5800 System’. The company will introduce the instrument in countries that accept the CE mark. 

Examining is one of the first lines of defense and it defends the patient’s general health. But, the laboratories often face issues such as increased patient testing, reimbursement complexities, and they require a diversified diagnostics menu. It is expected that Cobas 5800 System will help them to address all these challenges while delivering meaningful and fast results.

“Diagnostics continue to revolutionise how providers care for patients, and it is essential, now more than ever, that the healthcare community has access to reliable and accurate testing solutions. We are pleased that we can now offer a compact, fully-automated molecular system such as the cobas 5800 System. This new system helps to address the high demands on labs through greater efficiency, optimised workflows and cost savings, enabling them to deliver quality patient care.” 

Thomas Schinecker, CEO Roche Diagnostics

The Cobas 5800 System is a real-time PCR molecular testing solution with a small footprint and high performance. The System automates, consolidates, integrates, and standardizes data, making it a scalable, cost-effective option for smaller labs seeking big lab performance or larger labs wanting small lab agility.

The system is designed to provide a fully automated sample supply, transfer, and preparation workflow, as well as amplification and detection, result calculation, and delivery to the laboratory information system (LIS).

The recent addition has been made in line with the previous innovative systems Cobas 6800 and Cobas 8800 by Roche. The firm is expecting that, through this system, they will reach more patients around the world. Roche expects to be approved by the US Food and Drug Administration in Q3 2022.

Leave A Reply

Your email address will not be published.